The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanov S.V.

State Research Institute for Complex Issues of Cardiovascular Diseases Municipal Budget Healthcare Institution, Kemerovo, Russia

Volel' B.A.

Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii, Moskva

Syrkina E.A.

Chair of Preventive and Emergency Cardiology, Research Center of Mental Health RAS, Moscow, Russia

Ternovaia E.S.

Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii, Moskva

Troshina D.V.

Sechenov First Moscow State Medical University, Moscow, Russia

Grubova M.V.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Tolkacheva I.A.

Central State Medical Academy, Presidential Administration of the Russian Federation, Moscow, Russia

Rozhkov A.N.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Simonov A.N.

Mental Health Research Center, Moscow, Russia

A retrospective historical study evaluating the safe use of current antidepressants in cardiology practice

Authors:

Ivanov S.V., Volel' B.A., Syrkina E.A., Ternovaia E.S., Troshina D.V., Grubova M.V., Tolkacheva I.A., Rozhkov A.N., Simonov A.N.

More about the authors

Journal: Therapeutic Archive. 2017;89(12): 34‑42

DOI: 10.17116/terarkh2017891234-42

Read: 6264 times

Download PDF (RU)
Contact the author
Table of contents

A RETROSPECTIVE HISTORICAL STUDY EVALUATING THE SAFE USE OF CURRENT ANTIDEPRESSANTS IN CARDIOLOGY PRACTICE
A RETROSPECTIVE HISTORICAL STUDY EVALUATING THE SAFE USE OF CURRENT ANTIDEPRESSANTS IN CARDIOLOGY PRACTICE

To cite this article:

Ivanov SV, Volel' BA, Syrkina EA, et al. . A retrospective historical study evaluating the safe use of current antidepressants in cardiology practice. Therapeutic Archive. 2017;89(12):34‑42. (In Russ.)
https://doi.org/10.17116/terarkh2017891234-42

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy and tole­rability of azilsartan combined with amlo­dipine and amlo­dipine mono­therapy and combinations of amlo­dipine with other angiotensin II rece­ptor blockers. Russian Cardiology Bulletin. 2024;(4-2):161-171
Refralon for drug-induced cardioversion of atrial fibrillation in patients with coro­nary artery disease. Russian Cardiology Bulletin. 2024;(4-2):188-196
Inci­dence of diseases of the circulatory system in the working-age popu­lation of the Ural Fede­ral District in 2012—2022. Russian Journal of Preventive Medi­cine. 2025;(1):24-29
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Clinical outcomes after transcatheter aortic valve implantation in patients with concomitant coro­nary artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):45-52
Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chro­nic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
Adipocytokines as a predictor of the risk of adve­rse outcomes in patients with coro­nary heart disease and abdo­minal obesity after percutaneous coro­nary inte­rvention. Russian Journal of Preventive Medi­cine. 2025;(2):38-45
The Rela­tionship of obstructive sleep apnea with paro­xysmal atrial fibrillation in women suffered coro­nary heart disease and arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(2):61-66
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80
Abstract:

Aim. To confirm the data available in the literature on the cardiac safety of antidepressants. Subjects and methods. The archival data of 146 case histories were retrospectively analyzed. A study sample consisted of 96 cardiac inpatients regularly taking an antidepressant for more than 3 days during treatment for the underlying cardiovascular disease. The safe use of antidepressants was evaluated in terms of initial electrocardiogram (ECG) QTc interval changes, systolic and diastolic blood pressures (BP) (SBP and DBP), heart rate (HR), and hemorrhagic complications. The data obtained over periods of 3- and 6-8 days were analyzed. Results. The sample showed no clinically significant ECG QTc interval changes when taking regularly antidepressants within 8 days. Analysis of the dynamics of BP and HR in patients receiving antidepressants revealed no statistically significant differences in these indicators before and 3 and 6-8 days after drug administration. No case of hemorrhagic complications was seen in the study group taking antidepressants. Conclusion. The investigation generally confirms the high cardiac safety of new-generation antidepressants within at least the first week of therapy. Noteworthy are the low daily drug dosages (relatively specified in the instructions) that are sufficient for most cardiac patients with depressive disorders and an additional factor for minimizing adverse reactions.

Keywords:

antidepressants
safety
hypertension
coronary heart disease
depressive disorder

Authors:

Ivanov S.V.

State Research Institute for Complex Issues of Cardiovascular Diseases Municipal Budget Healthcare Institution, Kemerovo, Russia

Volel' B.A.

Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii, Moskva

Syrkina E.A.

Chair of Preventive and Emergency Cardiology, Research Center of Mental Health RAS, Moscow, Russia

Ternovaia E.S.

Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii, Moskva

Troshina D.V.

Sechenov First Moscow State Medical University, Moscow, Russia

Grubova M.V.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Tolkacheva I.A.

Central State Medical Academy, Presidential Administration of the Russian Federation, Moscow, Russia

Rozhkov A.N.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

Simonov A.N.

Mental Health Research Center, Moscow, Russia

Close metadata

References:

  1. Smulevich AB. Depression in psychiatric and medical practices. М.: MIA, 2015: 640 (In Russ.)
  2. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894-1898. https://doi.org/10.1161/hc4101.097519
  3. Van den Brink RHS, Van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial infarction and depression-intervention trial (MIND-IT). Am Heart J 2002;144:219-225. https://doi.org/10.1067/mhj.2002.123580
  4. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709. https://doi.org/10.1001/jama.288.6.701
  5. Taylor CB, Youngblood ME, Catellier D, et al. ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-798. https://doi.org/10.1001/archpsyc.62.7.792
  6. Jiang W, Krishnan KRR. Treatment of Depression in the Medically Ill. In: Ciraulo DA, Shader RI (eds.). Pharmacotherapy of Depression, Second Edition. LLC: Springer Science+Business Media, 2011:399-415.
  7. Kimmel, SE, Schelleman, H, Berlin, JA, Oslin, DW, Weinstein, RB, Kinman, JL, Lewis, JD. The effect of selective serotonin re‐uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. British journal of clinical pharmacology. 2011;72(3):514-517. https://doi.org/10.1111/j.1365-2125.2011.04008.x
  8. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20:137-140.
  9. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine — preliminary findings. Arch Gen Psychiatry. 2000;57(9):875-882. https://doi.org/10.1001/archpsyc.57.9.875
  10. Serebruany VL, Glassman AH, Malinin AI, et al. Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003; 108:939-944. https://doi.org/10.1161/01.CIR.0000085163.21752.0A
  11. Rechlin T. The effects of psychopharmacological therapy on heart rate variation. Nervenarzt. 1995;66:678-685. (In. Ger.)
  12. Yeragani V.K., Pesce V., Jayaraman A., et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002;52:418-429. https://doi.org/10.1159/000066390
  13. Yeragani VK, Roose S, Mallavarapu M, et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology. 2002;46:125-135. https://doi.org/10.1016/S0006-3223(02)01394-X
  14. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Shores-Wilson. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. American journal of Psychiatry. 2006;163(1):28-40. https://doi.org/10.1176/appi.ajp.163.1.28
  15. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009; 18:512-518. https://doi.org/10.1002/pds.1746
  16. Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiology and Drug Safety. 2008;17:587-592. https://doi.org/10.1002/pds.1607
  17. Wenzel-Seifert K, Wittmann M, Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry. 2010;43:279-281.
  18. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.
  19. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007;22:129-133. https://doi.org/10.1002/hup.834
  20. Letsas K, Korantzopoulos P, Pappas L, et al. QT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006;109(1):116-117. https://doi.org/10.1016/j.ijcard.2005.03.065
  21. Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30(5):437-455. https://doi.org/10.2165/00002018-200730050-00007
  22. Olié JP, Gourion D, Montagne A, et al. Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study. Neuropsychiatr Dis Treat. 2010;35(6):71-79. https://doi.org/10.1016/j.encep.2009.10.011
  23. Kamijima K, Hashimoto S, Nagayoshi E, Koyama T. Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression. Neuropsychiatr Dis Treat. 2013;9:555-565. https://doi.org/10.2147/NDT.S42915
  24. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002;5(3):479-498. https://doi.org/10.1517/14656566.3.5.479
  25. Hla KK, Boyd O. Mianserin and complete heart block. Hum Toxicol. 1987;6(5):401-402.
  26. Haefeli WE, Schoenenberger RA, Scholer A. Recurrent ventricular fibrillation in mianserin intoxication. BMJ. 1991;302(6773):415-416.
  27. Newman B, Crome P. The clinical toxicology of mianserin hydrochloride. Vet Hum Toxicol. 1979;21(Suppl):60-62.
  28. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033-1049. https://doi.org/10.1007/s40263-012-0010-5
  29. Rajskij VA. Psihotropnye sredstva v klinike vnutrennih boleznej. M.: Medicine; 1988:288. (In Russ.)
  30. Fiedler VB, Buchheim S, Nitz RE, Scholtholt J. Haemodynamic effects of pirlindole, a new tetracyclic antidepressant agent. Arzneimittelforschung. 1983;33(2):244-250.
  31. Zajcev VP, Kolcova TI. Primenenie triciklicheskih antidepressantov pri ishemicheskoj bolezni serdca. Klin med. 1980;6:30-35 (In. Russ.)
  32. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24(6):479-499. https://doi.org/10.2165/11534420-000000000-00000
  33. Donazzolo Y, Latreille M, Caillaud M-A, Mocaer E, Seguin L. Evaluation of the Effects of Therapeutic and Supratherapeutic Doses of Agomelatine on the QT/QTc Interval: A Phase I, Randomized, Double-blind, Placebo-controlled and Positive-controlled, Crossover Thorough QT/QTc Study Conducted in Healthy Volunteers. J Cardiovasc Pharmacol. 2014;64:440-451. https://doi.org/10.1097/FJC.0000000000000136
  34. Medvedev VE, Epifanov AV. Innovation method of depression treatment in patients with coronary artery disease. Obozrenie psihiatrii i medicinskoj psihologii imeni VM Bekhtereva. 2010;3:46-50. (In Russ.)
  35. Statsenko ME, Shilina NN, Turkina SV. The efficiency of Valdoxan use in the rehabilitation period after myocardial infarction in patients with type 2 diabetes mellitus and anxiety-depressive disorders. Psychiatry and psychopharmacotherapy. 2012;14(6):8-13. (In Russ.)
  36. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-285. https://doi.org/10.1081/CLT-120037428
  37. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64:192-197. https://doi.org/10.1111/j.1365-2125.2007.02849.x
  38. Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila). 2008;46:71-73. https://doi.org/10.1080/15563650701275322
  39. Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009;54(3):404-408. https://doi.org/10.1016/j.annemergmed.2009.04.016
  40. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010;196(5):354-358. https://doi.org/10.1192/bjp.bp.109.070219
  41. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 1. J Psychosoc Nurs Ment Health Serv. 2011;49(11):13-16. https://doi.org/10.3928/02793695-20111102-04
  42. Preskorn SH, Flockhart D. Guide to Psychiatric Drug Interactions. Primary Psychiatry. 2004;11(2):39-60.
  43. Malin DI. Side effect of psychotropic drugs. Higer school books. 2000:208. (In Russ.)
  44. Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575. https://doi.org/10.4088/JCP.09r05786blu
  45. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65 (12):1642-1653.
  46. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38(11):3049-51. https://doi.org/10.1161/STROKEAHA.107.491472
  47. van Walraven C., Mamdani M.M., Wells P.S., Williams J.I. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;22;323(7314):655-658. https://doi.org/10.1136/bmj.323.7314.655
  48. Castro VM, Gallagher PJ, Clements CC, et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open. 2012;2(2):e000544. https://doi.org/10.1136/bmjopen-2011-000544
  49. Mosolov SN. Spravochnoe rukovodstvo po psihotropnym i protivoehpilepticheskim preparatam razreshennym k primeneniyu v Rossii. М, 2002:173. (In Russ.)
  50. Andrade Ch, Sharma E. Serotonin reuptake inhibitors and risk of abnormal bleeding. In: Mago R. (ed.) Adverse effects of psychotropic treatments. Psychiatric Clinic of North America. 2016;39;3:413-426. https://doi.org/10.1016/j.psc.2016.04.010
  51. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;13;163(1):59-64. https://doi.org/10.1001/archinte.163.1.59
  52. Bazire S. Psychotropic Drug Directory. 2010. HealthComm UK Limited. 2011:552.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.